Moving Beyond JAK Inhibitors in Myeloproliferative Neoplasms

1 Pogledi
administrator
administrator
07/29/23

Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.

  • Kategorija

Prikaži više

0 Komentari Poredaj po

Nema komentara

Komentari na Facebooku

Sljedeći